泌乳素瘤的分子发病机制及治疗研究进展

Abstract
Figure/Table
References (35)
Related Citation (5)

Download: PDF (620 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Prolactinoma is a type of tumor caused by imbalance of pituitary gland secretion. Excessive secretion of prolactin leads to prolactinoma or complications related to prolactin secretion. Studies have found that disturbances in cell signaling pathways such as phosphatidylinositol-3-kinase-protein kinase B, transforming growth factor-β could cause abnormal expansion of prolactin cells, excessive secretion of prolactin, and eventually lead to the formation of prolactinoma. The current clinical treatment for prolactinoma mainly uses dopamine agonists, but also surgical treatment and radiation therapy. With the study of the molecular mechanism of its pathogenesis, new targets have been provided for the treatment of tumors, such as programmed death-1, programmed death-ligand-1 and other immunosuppressive targets. This article reviews the molecular mechanism and the progress of treatment of prolactinoma in order to better guide the early diagnosis and clinical treatment of prolactinoma.

Key words： Prolactinoma Molecular mechanism Phosphatidylinositol-3-kinase-protein kinase B signaling pathway Dopamine agonist

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DUAN Jiafeng1 ZHANG Qiujuan2 HU Chunmei1 SHI Yang2 ZHANG Huaibi1

Cite this article:

DUAN Jiafeng1 ZHANG Qiujuan2 HU Chunmei1 SHI Yang2 ZHANG Huaibi1. Advances in molecular pathogenesis and treatment of prolactinoma[J]. 中国医药导报, 2020, 17(31): 66-69.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I31/66

[1] Ezzat S，Asa SL，Couldwell WT，et al. The prevalence of pituitary adenomas：A systematic review [J]. Cancer，2004， 101（3）：613-619.
[2] Asa SL. Tumors of the Pituitary Gland [M]. AFIP Atlas of Tumor Pathology，1998.
[3] Rostad S. Pituitary adenoma pathogenesis：An update [J]. Curr Opin Endocrinol，2012，19（4）：322-327.
[4] Molitch ME. Prolactinoma in pregnancy [J]. Best Pract Res Clin Endocrinol Metab，2011，25（6）：885-896.
[5] Roof AK，Siwanon J，Tammy T，et al. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine [J]. Endocrinology，2018，159（6）：2421-2434.
[6] Takeda M，Otsuka F，Suzuki J，et al. Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas [J]. Biochem Biophys Res Commun，2003，306（4）：812-818.
[7] Wu MY，Hill CS. TGF-beta superfamily signaling in embryonic development and homeostasis [J]. Dev Cell，2009， 16（3）：329-343.
[8] Paez-Pereda M，Giacomini D，Refojo D，et al. Involvement of bone morphogenetic protein 4（BMP-4）in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk [J]. PNAS，2003，100（3）：1034-1039.
[9] Bilezikjian LM，Blount AL，Donaldson CJ，et al. Pituitary actions of ligands of the TGF-β family：activins and inhibins [J]. Reproduction，2006，132（2）：207-215.
[10] Principe M，Chanal M，Karam V，et al. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation [J]. Endocr-Relat Cancer，2018， 25（9）：795-806.
[11] De ST，Ye G，Liang YY，et al. Nodal Promotes Glioblastoma Cell Growth [J]. Front Endocrinol，2012，3：59.
[12] Recouvreux MV，Camilletti MA，Rifkin DB，et al. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas [J]. J Endocrinol，2016，228（3）：R73-R83.
[13] Li Z，Liu Q，Li C，et al. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas [J]. Mol Cell Endocrinol，2015，402：64-71.
[14] Hu B，Mao Z，Jiang X，et al. Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma [J]. Brain Res，2018，1698：204-212.
[15] Liu JC，Baker RE，Sun C，et al. Activation of Go-coupled Dopamine D2 Receptors Inhibits ERK1/ERK2 in Pituitary Cells a Key Step in the Transcriptional Suppression of the Prolactin Gene [J]. J Biol Chem，2002，277（39）：35819-35825.
[16] Spada A，Mantovani G，Lania A. Pathogenesis of prolactinomas [J]. Pituitary，2005，8（1）：7-15.
[17] Karreth FA，Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse [J]. Curr Opin Genet Dev，2009， 19（1）：4-11.
[18] Jackson TA，Koterwas DM，Bradford AP. Differential regulation of cell growth and gene expression by FGF-2 and FGF-4 in pituitary lactotroph GH4 cells [J]. Mol Cell Endocrinol，2006，247（1/2）：183-191.
[19] Nakagawa T，Mabry M，De Bustros A，et al. Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells [J]. Proc Natl Acad Sci，1987，84（16）：5923-5927.
[20] Booth A，Trudeau T，Gomez C，et al. Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype [J]. Mol Endocrinol，2014， 28（12）：1999-2011.
[21] Gillam MP，Molitch ME，Lombardi G，et al. Advances in the treatment of prolactinomas [J]. Endocr Rev，2006，27（5）：485-534.
[22] Casanueva FF，Molitch ME，Schlechte JA，et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas [J]. Clin Endocrinol，2006，65（2）：265-273.
[23] Webster J，Piscitelli G，Polli A，et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group [J]. N Engl J Med，1994，331（14）：904-909.
[24] Del Dotto P，Bonuccelli U. Clinical pharmacokinetics of cabergoline [J]. Clin Pharmacokinet，2003，42（7）：633-645.
[25] Holt RI，Barnett AH，Bailey CJ. Bromocriptine: old drug, new formulation and new indication [J]. Diabetes Obes Metab，2010，12（12）：1048-1057.
[26] Wong A，Eloy JA，Couldwell WT，et al. Update on prolactinomas. Part 2：Treatment and management strategies [J]. J Clin Neurosci，2015，22（10）：1568-1574.
[27] Ono M，Miki N，Amano K，et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro-and macroprolactinomas [J]. Clin Endocrinol，2010，95（6）：2672-2679.
[28] Karunakaran S，Page RCL，Wass JAH. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia [J]. Clin Endocrinol，2001，54（3）：295-300.
[29] Schlechte JA. Prolactinoma [J]. N Engl J Med，2003，349（21）：2035-2041.
[30] 何跃，雷霆，李龄.多巴胺激动剂耐受的垂体泌乳素腺瘤的研究进展[J].中国临床神经外科杂志，2006，11（3）：183-185.
[31] Popovic V，Simic M，Ilic LJ，et al. Growth hormone secretion elicited by GHRH，GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy [J]. Clin Endocrinol，1998，48（1）：103.
[32] Colao A，Di Sarno A，Landi ML，et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists：a prospective study in 110 patients [J]. J Clin Endocrinol Metab，2000，85（6）：2247-2252.
[33] Molitch ME. Dopamine resistance of prolactinomas [J]. Pituitary，2003，6（1）：19-27.
[34] Losa M，Mortini P，Barzaghi R，et al. Surgical treatment of prolactin-secreting pituitary adenomas：early results and long-term outcome [J]. J Clin Endocrinol Metab，2002，87（7）：3180-3186.
[35] Casanueva FF，Molitch ME，Schlechte JA，et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas [J]. Clin Endocrinol，2006，65（2）：265-273.